Cresco Labs will report third-quarter 2026 results on November 6, before the market opens, followed by a conference call at 8:30 a.m. ET, the company confirmed through Business Wire on October 15. The date gives investors a fixed checkpoint after a second quarter that showed sequential revenue growth but also a stock trading far below its 52-week high on both of its public listings.
What the Last Quarter Actually Showed
The second quarter of 2026 was, by the numbers, a reasonably solid one for a multi-state operator still working through a difficult margin environment. Revenue rose 15.00 percent sequentially to USD 173 million, according to ScanX News, while the standardized financial statement put the figure at USD 173.34 million alongside USD 16.80 million in net income. Adjusted EBITDA climbed 20.00 percent sequentially to USD 40 million, and adjusted gross profit reached USD 89 million - a 52.00 percent margin that, in an industry still squeezed by wholesale price compression and 280E tax treatment, counts as meaningful operating discipline. Margin expansion at that level typically reflects some combination of SKU rationalization, tighter control over inventory shrinkage, and better absorption of fixed costs across a vertically integrated footprint spanning cultivation, branded products, and Sunnyside retail locations in eight states.
That sounds tidy on paper, but the market has not been rewarding it. Cresco shares traded at EUR 0.55 on the Lang & Schwarz exchange on October 15, with a bid of EUR 0.53 and an ask of EUR 0.56 - a thin spread suggesting limited liquidity in that venue. On the Canadian listing, the stock closed at CAD 0.88 the same day, which places it 71.79 percent below its 52-week high of CAD 3.12. A negative price-to-earnings ratio of 1.96 and a market capitalization of CAD 311.6 million round out a picture of a company generating operating cash flow improvement while still carrying a loss-making earnings base on a trailing basis.
Why the Gap Between Operations and Valuation Matters
In practice, though, this disconnect is not unique to Cresco. Multi-state operators across the cannabis sector have spent the past several years managing a structural tax burden under Section 280E, compressed wholesale pricing in mature adult-use markets, and capital markets that remain wary of federally unresolved cannabis equities regardless of quarterly performance. Green Thumb Industries, by contrast, trades at a P/E of 11.70 with a market capitalization of CAD 1.98 billion, having moved only minus 1.09 percent - a reminder that investor confidence within the sector is uneven even among comparably sized operators. For dispensary-level operators and wholesale buyers watching these filings, the gap between improving adjusted EBITDA and a depressed share price is a signal worth tracking: it reflects how public markets price regulatory risk and rescheduling uncertainty separately from operating fundamentals.
What's Next on the Calendar
- October 30, 2026 - Cresco Labs annual and special meeting, a separate corporate governance milestone from the earnings cycle
- November 6, 2026 - third-quarter 2026 results released before market open, followed by an 8:30 a.m. ET conference call
- Key metrics to watch - revenue trajectory, adjusted gross margin sustainability near 52.00 percent, and whether adjusted EBITDA growth continues at the pace seen in the second quarter
For operators, suppliers, and investors tracking the multi-state landscape, the November 6 release will be the next real test of whether second-quarter margin gains were a one-time inventory or pricing effect, or the start of a steadier trend. Compliance costs, excise tax exposure, and state-by-state licensing pressure remain the backdrop against which any revenue number has to be read - a healthy top line alone does not resolve the valuation discount built into loss-making cannabis equities trading on Canadian and European exchanges.
